Nabsys Welcomes Genome Mapping Innovator Alka Chaubey as New Chief Medical Officer

Nabsys 2.0, LLC, renowned for its cutting-edge electronic genome mapping technology, has recently appointed Dr. Alka Chaubey, Ph.D., FACMG, as its Chief Medical and Genomics Officer. This strategic move is significant for the company as it aims to expand its capabilities and reach in the rapidly evolving field of genomics.

Dr. Chaubey joins Nabsys during a critical time as the company is gearing up to broaden the commercialization of its innovative electronic genome mapping (EGM) platform. Her role will encompass leading the strategical frameworks for medical and scientific affairs while forging strong partnerships with researchers and influential opinion leaders in the field. This is vital for advancing the adoption of Nabsys's OhmX™ platform, especially as genomic analysis gains importance in various medical applications, including cancer diagnostics and gene therapies.

Barrett Bready, M.D., founder and CEO of Nabsys, expressed his enthusiasm about Dr. Chaubey's arrival. He stated that her extensive expertise would be instrumental for Nabsys as they transition into a new phase of genome mapping technology. Over recent years, the importance of identifying structural variants in genetic data has become increasingly clear, often revealing significant information that conventional methods may overlook. As Nabsys works to make high-resolution structural variant analysis accessible on a global scale, Dr. Chaubey's leadership is expected to play a pivotal role.

Dr. Chaubey elaborated on her vision for Nabsys, emphasizing her commitment to collaborating with global teams to enhance the understanding of biological variations through advanced genome mapping techniques. She noted that the OhmX Platform uniquely combines the precision required for insightful structural variant analysis with user-friendly features aimed at increasing its adoption by laboratories worldwide. Dr. Chaubey also highlighted the strength of Nabsys's leadership, reinforcing the company's plans for growth backed by strong financial ties with partners like Hitachi High-Tech.

With over 20 years of experience in molecular genetics and cytogenomics, Dr. Chaubey is well-equipped to tackle the challenges ahead. Before joining Nabsys, she served as Chief Medical Officer at Bionano Genomics, where she was instrumental in the acceptance of Optical Genome Mapping (OGM) technology in various commercial applications.

Dr. Chaubey's credentials include dual board certifications in Clinical Cytogenetics and Genomics, as well as Clinical Molecular Genetics and Genomics. Her involvement in numerous prestigious professional organizations, coupled with her extensive publication record, underscores her as a leader within the scientific community focused on cytogenomics and the broader field of genetic diagnostics.

She has held significant roles in developing groundbreaking genomic tests previously, such as the CNGnome™ assay, emphasizing her commitment to innovation in genomic testing technology. Dr. Chaubey also holds academic positions, including as the Scientific Director of the Cytogenetics Laboratory at Augusta University, where she continues to influence the advancements in genomics.

Nabsys's OhmX Platform represents a significant step forward in understanding genome structures and opens doors to further exploration in cytogenetics and gene therapy. With Dr. Chaubey steering the company's scientific focus, Nabsys is poised for rapid progression in making genomic analysis not only more accessible but also fundamentally impactful across research and clinical settings.

As the company continues to grow and innovate under Dr. Chaubey's leadership, it remains dedicated to enhancing the quality and accessibility of genomic research tools, which have the potential to transform patient care and outcomes in various medical fields.

For those looking to explore the future of genome mapping and its implications in research and healthcare, Nabsys stands at the forefront, ready to lead the industry into this new era of molecular exploration.